PROTEOSTASIS THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PTI and Encourages Investors to Contact the Firm NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...

Proteostasis Therapeutics Announces Closing of Follow-On Public Offering of Common Stock CAMBRIDGE, Mass., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused...

Proteostasis Therapeutics Issues Mid-Year Corporate Update on Cystic Fibrosis Pipeline Programs CAMBRIDGE, Mass., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...

Proteostasis Therapeutics, Inc. Presents New Data Demonstrating Potential for Genotype-Agnostic and Combination Therapies for People with Cystic Fibrosis CAMBRIDGE, Mass., March 30, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...

Proteostasis Therapeutics, Inc. Announces Scientific Presentations at 13th Annual European Cystic Fibrosis Society Basic Science Conference CAMBRIDGE, Mass., March 28, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...